Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and Tolerability of HCP1803 in Healthy Male Volunteers
NCT05723549Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HCP-1803 in hypertension (HTN) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to the Last Measurable Concentration. Started Feb 2023; status: completed.
02
Drugs
HCP-1803
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05723549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05723549.